What is the catalog number for BIM-23190?

The catalog number for BIM-23190 is HY-P3124.

What sizes are available for BIM-23190?

BIM-23190 is available in the following size(s): 1 Each.

Is BIM-23190 in stock?

BIM-23190 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures BIM-23190?

BIM-23190 is manufactured by QuantiMol.

What is the estimated delivery time for BIM-23190?

Estimated delivery time for BIM-23190 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for BIM-23190?

The safety data sheet for BIM-23190 is available here: http://file.medchemexpress.com/batch_PDF/HY-P3124/.

BIM-23190

BIM-23190, a somatostatin analog, a selective SSTR2 and SSTR5 agonist, exhibits Ki values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly[1][3].

Product Specifications

CAS Number

182153-96-4

UNSPSC

12352209

Target

Somatostatin Receptor

Type

Peptides

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bim-23190.html

Solubility

10 mM in DMSO

Smiles

O=C(N[C@H](C(N[C@H](C(N1)=O)CC)=O)CCCCN)[C@H](NC([C@@H](NC([C@H](CSSC[C@H]1C(N[C@H](C(N)=O)[C@H](O)C)=O)NC([C@H](NC(CN(CC2)CCN2CCO)=O)CC3=CC=CC=C3)=O)=O)CC(C=C4)=CC=C4O)=O)CC5=CNC6=CC=CC=C56

Molecular Formula

C57H79N13O12S2

Molecular Weight

1202.45

References & Citations

[1]I Shimon, et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest. 1997 Nov 1;100 (9) :2386-92.|[2]Federica Barbieri, et al. Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice. Am J Physiol Endocrinol Metab. 2009 Nov;297 (5) :E1078-88.|[3]T J Gillespie, et al. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. J Pharmacol Exp Ther. 1998 Apr;285 (1) :95-104.